64 assets in Lung Adenocarcinoma

Therapeutic assets addressing Lung Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Carboplatin Lung Adenocarcinoma	Guangdong Association of Clinical Trials	P3	BBB (72)
Cyclophosphamide Lung Adenocarcinoma	Anusha Kalbasi	P2	BBB (72)
Cis-Diamminedichloroplatinum Ii Lung Adenocarcinoma	Guangdong Association of Clinical Trials	P3	BB (70)
Etoposide Lung Adenocarcinoma	Guangdong Association of Clinical Trials	P3	BB (70)
Nivolumab Lung Adenocarcinoma	Emory University	P3	BB (70)
Docetaxel Lung Adenocarcinoma	Sichuan Baili Pharmaceutical Co., Ltd.	P3	BB (69)
Vinorelbine Ditartrate Lung Adenocarcinoma	AIO-Studien-gGmbH	P3	BB (68)
Pembrolizumab Lung Adenocarcinoma	Rabin Medical Center	P2	B (62)
Ipilimumab Lung Adenocarcinoma	National Cancer Institute (NCI)	P3	B (60)
Si-B001 Lung Adenocarcinoma	Sichuan Baili Pharmaceutical Co., Ltd.	P3	B (60)
Methoxyamine Lung Adenocarcinoma	National Cancer Institute (NCI)	P2	B (58)
Durvalumab Lung Adenocarcinoma	University of British Columbia	P2	B (57)
Fludarabine Lung Adenocarcinoma	Anusha Kalbasi	P1/2	B (57)
Pegfilgrastim Lung Adenocarcinoma	Wake Forest University Health Sciences	P2	B (57)
Atirmociclib Lung Adenocarcinoma	Pfizer	P2	CCC (53)
Avutometinib Lung Adenocarcinoma	Emory University	P2	CCC (53)
Defactinib Lung Adenocarcinoma	Emory University	P2	CCC (53)
Enzalutamide Lung Adenocarcinoma	Pfizer	P2	CCC (53)
Fluorouracilum Lung Adenocarcinoma	Northwestern University	P2	CCC (53)
Fulvestrant Lung Adenocarcinoma	Pfizer	P2	CCC (53)
Hydroxychloroquine Lung Adenocarcinoma	Northwestern University	P2	CCC (53)
Letrozole Lung Adenocarcinoma	Pfizer	P2	CCC (53)
lp-300 Lung Adenocarcinoma	Lantern Pharma Inc.	P2	CCC (53)
Midazolam Lung Adenocarcinoma	Pfizer	P2	CCC (53)
Nivestim Lung Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Oral Restorative Microbiota Therapy Lung Adenocarcinoma	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Rain-32 Lung Adenocarcinoma	Rain Oncology Inc	P2	CCC (53)
Serplulimab Lung Adenocarcinoma	Fujian Cancer Hospital	P2	CCC (53)
Sotorasib Lung Adenocarcinoma	SWOG Cancer Research Network	P2	CCC (53)
Tepotinib Lung Adenocarcinoma	EMD Serono Research & Development Institute, Inc.	P2	CCC (53)
Tislelizumab Lung Adenocarcinoma	Jun Liu	P2	CCC (53)
Abemaciclib Lung Adenocarcinoma	Tango Therapeutics, Inc.	P1/2	CCC (48)
Cish Inactivated Tumor Infiltrating Lymphocytes Lung Adenocarcinoma	Intima Bioscience, Inc.	P1/2	CCC (48)
Neoantigen Specific Tcr-T Cell Drug Product Lung Adenocarcinoma	Alaunos Therapeutics	P1/2	CCC (48)
tng456 Lung Adenocarcinoma	Tango Therapeutics, Inc.	P1/2	CCC (48)
Atamparib Lung Adenocarcinoma	Nerviano Medical Sciences (Shanghai) Ltd.	P1/2	CC (47)
Devimistat Lung Adenocarcinoma	Northwestern University	P2	CC (47)
Spartalizumab Lung Adenocarcinoma	SOLTI Breast Cancer Research Group	P2	CC (46)
Palacaparib Lung Adenocarcinoma	AstraZeneca	P1/2	CC (45)
Saruparib Lung Adenocarcinoma	AstraZeneca	P1/2	CC (45)
SL-28 Lung Adenocarcinoma	Second Life Therapeutics	P1/2	CC (45)
tng260 Lung Adenocarcinoma	Tango Therapeutics, Inc.	P1/2	CC (45)
Torvutatug Samrotecan Lung Adenocarcinoma	AstraZeneca	P1/2	CC (45)
Veliparib Lung Adenocarcinoma	National Cancer Institute (NCI)	P1/2	CC (45)
ct-95 Lung Adenocarcinoma	Context Therapeutics Inc.	P1	CC (43)
ide892 Lung Adenocarcinoma	IDEAYA Biosciences	P1	CC (43)
Imp-321 Lung Adenocarcinoma	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	P1	CC (43)
MAT2A-IN-9 Lung Adenocarcinoma	IDEAYA Biosciences	P1	CC (43)
mgc028 Lung Adenocarcinoma	MacroGenics	P1	CC (43)
nm32-2668 Lung Adenocarcinoma	Numab Therapeutics AG	P1	CC (43)

Showing 1 to 50 of 64 assets

PreviousPage 1 of 2Next